Table 1.
Summary of bioactivities of metal-based CO-RMs in vivo via oral administration
| Compound | Activity | Animal model | Dosage | COHb (%) | Side product control | Ref |
|---|---|---|---|---|---|---|
| CORM-2 | gastric injury | rats | 5 mg/kg 10 mg/kg | 1.6% (5mg/kg) 2.2% (50mg/kg) | RuCl3 | [137] |
| CORM-A1 | cerebrovascular dysfunction | piglets | 2 mg/kg | NA | B(OH)3 | [128] |
| ALF-186 | acute toxicity evaluation | mice | 500 mg/kg | 35%-40% | NA | [150] |
| CORM-401 | obesity | mice | 15 mg/kg 30 mg/kg | 2.5% 4.5% | iCORM | [139] |
| HYCO-4 | inflammation | mice | 3 mg/kg | 4% | NA | [141] |
| HYCO-10 | inflammation | mice | 3 mg/kg | 2% | NA | [141] |
| HYCO-3 | inflammation | mice | 40 mg/kg | 5% | NA | [143] |
| HYCO-6 | Skin wound | mice | 40 mg/kg | 2% | NA | [145] |
| HYCO-3 HYCO-13 | Psoriasis, multiple sclerosis | mice | 25 mg/kg | 2% 5% | NA | [145] |
| CAI-CORM | rheumatoid arthritis | rats | 10-100 mg/kg | NA | NA | [165] |
| M-OCORS | colitis | mice | 2 tablets | 0.69% | abrogated - CORM-2 | [158] |
| M-OCORS | postoperative ileus | mice | 20 tablets | 5.2% | NA | [161] |
| SMA/CORM2 | Rheumatoid Arthritis | mice | 20 mg/kg | NA | NA | [162] |